Twitter LinkedIn Français English CLINICAL STRATEGY COMMITTEE Our clinical strategy committee is responsible for analyzing and reviewing our clinical and regulatory strategy. It meets, at least once a year, and makes recommendations to the board of directors regarding our clinical and regulatory development strategy. Martine George – Independent Director Martine Ortin George, M.D. has served as a member of our board of directors since 2014. She currently serves as principal and senior executive consultant-life sciences for Global Development Inc. Dr. George held the position of Vice President in charge of Global Medical Affairs for Oncology at Pfizer from 2010 to 2015. Previously, Dr. George held the positions of Senior Vice President and Chief Medical Officer at GPC Biotech and Senior Vice President, Head of the Oncology Department at Johnson & Johnson. She is a qualified gynecologist and oncologist, trained in France and in Montreal. Dr. George began her career as Chief of Service at the Institut Gustave Roussy (France), was a visiting professor at the Memorial Sloan Kettering Cancer Center, and then held positions of increasing responsibility at Lederle Laboratories (a predecessor company to Pfizer Inc.), Sandoz (now a division of Novartis AG) and Rhoˆne-Poulenc Rorer (today part of Sanofi). Luc Dochez – Independent Director Luc Dochez, Pharm.D. has served as a member of our board of directors since 2015. He became Chief Executive Officer of Tusk Therapeutics N.V., a private company focused on developing novel immuno-oncology products. Mr. Dochez has over 15 years of experience in the biotechnology industry. He served as the Chief Business Officer and Senior Vice President of Business Development of Prosensa Holding N.V., a biotechnology company, from November 2008 until its acquisition by BioMarin Pharmaceutical Inc. in January 2015. Before joining Prosensa, he served as Vice President of Business Development at TiGenix, Director Business Development at Methexis Genomics, and a consultant at Arthur D. Little. Mr. Dochez holds a Pharm.D. degree and a postgraduate degree in business economics from the University of Leuven (Belgium) and an M.B.A. degree from Vlerick Management School (Belgium). Melanie Rolli – Independent Director Dr. Melanie Rolli is a member of our board of directors since March 12, 2020. Dr Rolli is the CEO of PIQUR Therapeutics AG, a Basel-based clinical stage biotech company. Previously, Melanie Rolli was at Novartis Pharmaceuticals AG for 14 years, where she held positions of increasing responsibilities across the Drug Development, Safety, and Medical Affairs functions. At Novartis, she spent eight years in the United States in global and local positions and six years at Swiss headquarters in regional and global senior leadership roles in Oncology and across the company’s portfolio. Prior to joining Novartis, she worked as a post-doctoral cancer research physician at SCRIPPS Research Institute for Molecular and Experimental Medicine in La Jolla, California, and as a clinician and researcher in Germany. Dr. Rolli graduated from the University of Heidelberg with a doctorate in medicine and pharmacology. Philippe Archinard – Independent Director Philippe Archinard, Ph.D. has served as a member of our board of directors since 2013. Dr. Archinard is Deputy CEO, Innovation and Scientific Partnerships of the Institut Mérieux. He was General Manager, Chief Executive Officer and director of Transgene from 2004 to 2020, after spending 15 years in various senior positions with bioMérieux, including directing its U.S. subsidiary. Prior to joining Transgene, he served as chief executive officer of Innogenetics N.V., from 2000 to December 2004. Dr. Archinard is a chemical engineer, holds a Ph.D. in biochemistry from the University of Lyon (France), and completed Harvard Business School’s Program of Management PMD. Investors Corporate Governance Board of Directors Audit Committee Remuneration and Appointment Committee Clinical Strategy Committee Stock Market Data SEC Filings AMF Regulated Information Shareholders Meeting Financial Calendar Analyst Coverage Webcasts Corporate Presentation Erytech PharmaSA 60 Avenue Rockefeller 69008 Lyon France Erytech Pharma Inc. 1 Main Street, Suite 300 Cambridge, MA 02142 USA About Us Technology Platform Pipeline Investors Newsroom Contact Opens in a new tab Opens in a new tab Terms & Conditions Copyright © 2021. Erytech Pharma. All rights reserved. By visiting this website, you are giving your consent for cookies to be used for us to improve your navigation experience.OKLEARN MORE Français English